

Datasheet for ABIN7160065

anti-MAP4K2 antibody (AA 386-469)[Go to Product page](#)**2** Images

Overview

Quantity:	100 µg
Target:	MAP4K2
Binding Specificity:	AA 386-469
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This MAP4K2 antibody is un-conjugated
Application:	ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Product Details

Immunogen:	Recombinant Human Mitogen-activated protein kinase kinase kinase kinase 2 protein (386-469AA)
Isotype:	IgG
Cross-Reactivity:	Human
Purification:	>95%, Protein G purified

Target Details

Target:	MAP4K2
Alternative Name:	MAP4K2 (MAP4K2 Products)
Background:	Background: Serine/threonine-protein kinase which acts as an essential component of the MAP

Target Details

kinase signal transduction pathway. Acts as a MAPK kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion.

Aliases: B lymphocyte serine/threonine protein kinase antibody, B lymphocyte serine/threonine-protein kinase antibody, BL44 antibody, GC kinase antibody, GCK antibody, Germinal center kinase antibody, germinal centre kinase (GC kinase) antibody, M4K2_HUMAN antibody, Map4k2 antibody, MAPK/ERK kinase kinase kinase 2 antibody, MEK kinase kinase 2 antibody, MEKKK 2 antibody, Mitogen activated protein kinase kinase kinase kinase 2 antibody, Mitogen-activated protein kinase kinase kinase kinase 2 antibody, Rab8 interacting protein antibody, Rab8 interacting protein, formerly antibody, Rab8-interacting protein antibody, RAB8IP antibody, RAB8IP, formerly antibody

UniProt: [Q12851](#)

Application Details

Application Notes: Recommended dilution: IHC:1:500-1:1000, IF:1:50-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be


Handling

handled by trained staff only.

Storage: -20 °C,-80 °C


Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Images



Immunohistochemistry

Image 1. IHC image of ABIN7160065 diluted at 1:500 and staining in paraffin-embedded human endometrial cancer performed on a Leica Bond™ system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.



Immunofluorescence

Image 2. Immunofluorescence staining of HepG2 cells with ABIN7160065 at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).